BiCNU and Penbutolol
Determining the interaction of BiCNU and Penbutolol and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this minor interaction is not currently available. Some minor drug interactions may not be clinically relevant in all patients. Minor drug interactions do not usually cause harm or require a change in therapy. However, your healthcare provider can determine if adjustments to your medications are needed.
Professional:Some alkylating agents may significantly increase the free fraction of penbutolol by displacing it from plasma protein-binding sites (alpha-1 acid glycoprotein). Data are available for carmustine (BCNU) and mechlorethamine. The clinical significance is unknown. Clinicians should be aware of the interaction and observe patients for increased beta-blockade.
- Aguirre C, Rodriguez-Sasiain JM, Calvo R "Decrease in penbutolol protein binding as a consequence of treatment with some alkylating agents." Cancer Chemother Pharmacol 34 (1994): 86-8
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- BiCNU-Penciclovir
- BiCNU-Penciclovir topical
- BiCNU-Penicillamine
- BiCNU-Penicillamine Capsules
- BiCNU-Penicillin
- BiCNU-Penicillin G Sodium Injection
- Penbutolol-Bictegravir Sodium, Emtricitabine, and Tenofovir Alafenamide Fumarate
- Penbutolol-Bictegravir, emtricitabine, and tenofovir
- Penbutolol-Bictegravir, Emtricitabine, and Tenofovir Alafenamide
- Penbutolol-Bidex-A
- Penbutolol-BiDil
- Penbutolol-Bifera